Table 5.

Recommended Dosages for Treatment and Chemoprophylaxis for Influenza Antiviral Medications

ANTIVIRAL	TREATMENT DOSING	CHEMOPROPHYLAXIS DOSING	ADVERSE EVENTS
Oseltamivir  Adults  Children >12 mo   ≤15 kg   >15–23 kg   >23–40 kg   >40 kg  Infants 9–11 mo  Term infant 0–8 mo  Preterm infants   <38 wk   38–40 weeks   >40 weeks  (Postmenstrual age)	5-d oral course  75 mg, twice daily  30 mg, twice daily  45 mg, twice daily  60 mg, twice daily  75 mg, twice daily  3.5 mg/kg per dose, twice daily  3.0 mg/kg per dose, twice daily  1.0 mg/kg per dose, twice daily 2.0  mg/kg per dose, twice daily 3.0  mg/kg per dose, twice daily	7-d oral course  75 mg, once daily  30 mg, once daily  45 mg, once daily  60 mg, once daily  75 mg, once daily  3.5 mg/kg per dose, once daily  3–8 mo:  3.0 mg/kg/dose, once daily  0–3 mo:  Consult with an infectious disease specialist	Nausea, vomiting, headache, diarrhea, rare transient neuropsychiatric events, severe cutaneous adverse reactions
Zanamivir  Adults  Children	5-d inhaled course  10 mg (two 5-mg puffs, twice daily)  ≥7 y  10 mg (two 5-mg puffs, twice daily)	7-d inhaled course  10 mg (two 5-mg puffs, once daily)  ≥5 y  10 mg (two 5-mg puffs, once daily)	Risk of bronchospasm (avoid in people with chronic lung disease), dizziness, rare transient neuropsychiatric events, severe cutaneous adverse reactions
Peramivir  6 mo–12 y  ≥13 y	1 infusion  12 mg/kg dose (600 mg maximum)  IV  600 mg dose IV	Not recommended	Diarrhea, rare transient neuropsychiatric events, severe cutaneous adverse reactions
Baloxavir  ≥5 y   <20 kg   20 kg–<80 kg   ≥80 kg	1 oral dose  2 mg/kg once  40 mg once  80 mg once	1 oral dose  2 mg/kg once  40 mg once  80 mg once	Nausea, vomiting, diarrhea

IV=intravenous.

Adapted from Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2022–2023. Pediatrics. 2022;150(4):e2022059275. (22)